Skip to main content

Advertisement

SpringerLink
Log in

Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Drug-induced lung injury (DLI) comprises a wide variety of pathologies, each with a unique imaging pattern, so there are no characteristic imaging findings to establish diagnosis. When DLI is suspected, evaluation must exclude progression of underlying disease, infection, and mimicking diseases. Correct diagnosis requires integration of clinical information and radiologic, laboratory, and pathological findings when available. We describe the radiologic findings of DLI, the roles of the findings in the management of patients with DLI, and the limitations of radiologic diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Camus P, Fanton A, Bonniaud P et al (2004) Interstitial lung disease induced by drug and radiation. Respiration 71:301–326

    Article  PubMed  Google Scholar 

  2. Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348–1357

    Article  PubMed  Google Scholar 

  3. Gotoh A, Ohyashiki K, Oshimi K et al (2006) Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology. Int J Hematol 84:406–412

    Article  PubMed  CAS  Google Scholar 

  4. Sakai F, Noma S, Kurihara Y et al (2005) Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 15:173–179

    Article  PubMed  Google Scholar 

  5. Inoue A, Saijo Y, Maemondo M et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137–139

    Article  PubMed  Google Scholar 

  6. Japanese Respiratory Society (2012) Guideline for the diagnosis and treatment of drug-induced lung injury. Medical Review Publishers, Tokyo

    Google Scholar 

  7. Alarcón GS, Kremer JM, Macaluso M et al (1997) Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter case-control study. Methotrexate-Lung Study Group. Ann Intern Med 127:356–364

    PubMed  Google Scholar 

  8. Erasmus JJ, McAdams HP, Rossi SE (2002) Drug-induced lung injury. Semin Roentgenol 37:72–81

    Article  PubMed  Google Scholar 

  9. Akira M, Ishikawa H, Yamamoto S (2002) Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology 224:852–860

    Article  PubMed  Google Scholar 

  10. Rossi SE, Erasmus JJ, McAdams HP et al (2000) Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20:1245–1259

    PubMed  CAS  Google Scholar 

  11. Cleverley JR, Screaton NJ, Hiorns MP et al (2002) Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 57:292–299

    Article  PubMed  Google Scholar 

  12. Ichikado K, Suga M, Gushima M et al (2000) Hyperoxia-induced diffuse alveolar damage in pigs: correlation between thin-section CT and histopathologic findings. Radiology 216:531–538

    PubMed  CAS  Google Scholar 

  13. Tomiyama N, Müller NL, Johkoh T et al (2001) Acute respiratory distress syndrome and acute interstitial pneumonia: comparison of thin-section CT findings. J Comput Assist Tomogr 25:28–33

    Article  PubMed  CAS  Google Scholar 

  14. Ichikado K, Suga M, Muranaka H et al (2006) Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases. Radiology 238:321–329

    Article  PubMed  Google Scholar 

  15. Imokawa S, Colby TV, Leslie KO et al (2000) Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 15:373–381

    Article  PubMed  CAS  Google Scholar 

  16. Arakawa H, Yamasaki M, Kurihara Y et al (2003) Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imag 18:231–236

    Article  Google Scholar 

  17. Tokuda H, Sakai F, Yamada H et al (2008) Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 47:915–923

    Article  PubMed  Google Scholar 

  18. Souza CA, Müller NL, Johkoh T et al (2006) Drug-induced eosinophilic pneumonia: high-resolution CT findings in 14 patients. AJR Am J Roentogenol 186:368–373

    Article  Google Scholar 

  19. Ben m’rad M, Leclerc-Mercier S, Blanche P et al (2009) Drug-induced hypersensitivity syndrome: clinical and biologic disease pattern in 24 patients. Medicine (Baltim) 88:131–140

    Article  Google Scholar 

  20. Cameron RJ, Kolbe J, Wilsher ML et al (2000) Bronchiolitis obliterans organizing pneumonia associated with the use of nitrofurantoin. Thorax 55:249–251

    Article  PubMed  CAS  Google Scholar 

  21. Kameda H, Tokuda H, Sakai F et al (2011) Clinical and radiological features of acute-onset diffuse interstitial diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 50:305–313

    Article  PubMed  CAS  Google Scholar 

  22. Komano Y, Harigai M, Koike R et al (2009) Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61:305–312

    Article  PubMed  CAS  Google Scholar 

  23. Tanaka M, Sakai R, Koike R et al. (2012) Pneumocystis jiroveci pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol (Epub ahead of print)

  24. Ohnishi K, Sakai F, Kudoh S et al (2006) Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 20:1162–1164

    Article  PubMed  CAS  Google Scholar 

  25. Merc-Serono Co. Ltd., Bristol-Meyers Co., Ltd. (2009) Post-marketing survey of adverse reaction of Erbitux™ (cetuximab) injection 100 mg. Tokyo

  26. Takeda Pharmaceutical Co., Ltd. (2001) Special post-marketing survey of adverse reaction of Vectebix™ (panitumab) 100 mg injection. Tokyo

  27. Hagiwara K, Sato T, Takagi-Kobayashi S et al (2007) Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 34:1151–1154

    PubMed  Google Scholar 

  28. Novartis Pharma (2011) Result of drug-induced interstitial pneumonia in special post-marketing survey of Affinitiol™ (everolimus) tablet

  29. Pfizer Co., Ltd. (2011) Guide of appropriate use of Tricel™ (temsirolius) injection 25 mg

  30. Maroto JP, Hudes G, Dutcher JP et al (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29:1750–1756

    Article  PubMed  CAS  Google Scholar 

  31. White DA, Camus P, Endo M et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396–403

    Article  PubMed  Google Scholar 

  32. Champion L, Stern M, Israël-Biet D et al (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144:505–509

    PubMed  Google Scholar 

  33. Koike R, Tanaka M, Komano Y et al (2011) Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients. Pulm Pharmacol Ther 24:401–406

    Article  PubMed  CAS  Google Scholar 

  34. Kennedy JI, Myers JL, Plumb VJ et al (1987) Amiodarone pulmonary toxicity. Clinical, radiologic, and pathologic correlations. Arch Intern Med 147:50–55

    Article  PubMed  CAS  Google Scholar 

  35. Kuhlman JE, Scatarige JC, Fishman EK et al (1987) CT demonstration of high attenuation pleural-parenchymal lesions due to amiodarone therapy. J Comput Assist Tomogr 11:160–162

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This paper is partly supported by a grant to the Diffuse Lung Diseases Research Group from the Ministry of Labor, Health and Welfare of Japan.

Conflict of interest

We do not have any real and potential conflict of interest except as described below. Fumikazu Sakai has received advisory fees from Chugai Pharmaceuticals Co. Ltd., Beyer Pharmaceuticals Co. Ltd., Pfizer Pharmaceuticals Co. Ltd., Takeda Pharmaceuticals Co. Ltd., MSD Co. Ltd., Jansen Pharmaceuticals Co. Ltd., and Merc Serono Co. Ltd. Fumikazu Sakai received lecture fees from Eizai Co. Ltd., Daiichi Sankyo Pharmaceuticals Co. Ltd., Kyorin Pharmaceuticals Co. Ltd., and Shionogi Pharmaceuticals Co. Ltd. The department of Fumikazu Sakai received research funds from Eizai Co. Ltd., Beyer Co. Ltd., Kovidien Japan Co. Ltd., LTT Bio Co. Ltd., and Daiichi-Sankyo Pharmaceuticals Co. Ltd. Takeshi Johkoh received consultant fees from Chugai Pharmaceuticals Co. Ltd., Beyer Pharmaceuticals Co. Ltd., and Shionogi Pharmaceuticals Co. Ltd. Takeshi Johkoh received a lecture fee from Chugai Pharmaceuticals Co. Ltd., Shionogi Pharmaceuticals Co. Ltd., Daiichi-Sankyo Pharmaceuticals Co. Ltd., Kyorin Pharmaceuticals Co. Ltd., Beyer Pharmaceuticals Co. Ltd., and Eizai Co. Ltd. Hiroaki Arakawa received advisory fees from Chugai Pharmaceuticals Co. Ltd. and Jansen Pharmaceuticals Co. Ltd. Masahiko Kusumoto received advisory fees from Chugai Pharmaceuticals Co. Ltd., Pfizer Co. Ltd., and Jansen Pharmaceutical Co. Ltd. The department of Takahashi Masahiro received research funds from Eizai Co. Ltd., Bayer Co. Ltd., Kovidien Japan, LTT Bio Co. Ltd., and Daiichi Sankyo Pharmaceuticals Co. Ltd.

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Saitama International Medical Center, Saitama Medical University, Hidaka, Saitama, 350-1298, Japan

    Fumikazu Sakai & Masahiro Takahashi

  2. Department of Diagnostic Radiology, Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami, Japan

    Takeshi Johkoh

  3. Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

    Masahiko Kusumoto

  4. Department of Radiology, Dokkyo University Hospital, Mibu-machi, Japan

    Hiroaki Arakawa

Authors
  1. Fumikazu Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Johkoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahiko Kusumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroaki Arakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masahiro Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fumikazu Sakai.

About this article

Cite this article

Sakai, F., Johkoh, T., Kusumoto, M. et al. Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings. Int J Clin Oncol 17, 542–550 (2012). https://doi.org/10.1007/s10147-012-0489-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0489-2

Keywords

Search

Navigation